Home | GSK US
October 24 2024 New data for AREXVY, GSK’s respiratory syncytial virus vaccine, show potential to help protect a broader group of adults at increased risk for RSV disease. October 16 2024 …
At a glance | GSK US
At a glance. Getting Ahead Together means preventing disease as well as treating it. Globally, our portfolio spans vaccines, specialty and general medicines, with R&D focused on science of the …
Products - GSK US
General medicines include our inhaled medicines for asthma and COPD, antibiotics and medicines for skin diseases, in a portfolio which includes pre-launch R&D assets, growth and …
Company | GSK US
GSK has a significant footprint in the US across commercial, R&D, manufacturing, and corporate functions. We employ ~15,000 people across the US and have two corporate hubs. Explore …
Contact us - GSK
Contact us online at GSK for You. RRC - a reimbursement support program that helps patients and healthcare professionals in the US with coverage, coding and reimbursement issues for …
Careers - GSK US
At GSK, we unite science, technology and talent to get ahead of disease together. We aim to positively impact the health of 2.5 billion people by the end of the decade, as a successful, …
Search jobs | GSK US
Experienced professionals. We strive to attract the best people and create an environment that empowers and inspires. Eplore the opportunities currently available.
Vaccines | GSK US
We deliver over two million vaccine doses per day to people living in over 160 countries. The vaccines in our portfolio have been helping to protect people from serious disease for well over …
Locations | GSK US
Trade marks are owned by or licensed to the GSK group of companies. GSK plc. Registered in England and Wales No. 3888792. Registered office: 79 New Oxford Street, London. United …
Specialty | GSK US
GSK has been an established leader in eosinophil research for over 25 years. We are currently supporting more than 60 studies worldwide across 24 countries to progress eosinophil science …